SLC5A2 and type 2 diabetes mellitus: Similar findings were reported by Udell et al. [22] who concluded that SGLT2 inhibitors play an important role in improving cardiorenal outcomes in patients with T2DM, chronic kidney disease, and chronic heart failure [44].